Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric J Small

Showing results (301-310 of 361) with videos related to

Pageof 37
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2023
External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate CancerSusan Halabi, Qian Yang, Akash Roy, et al.
Urologic Oncology|December 17, 2022
Quality of life for men with metastatic castrate-resistant prostate cancer participating in an aerobic and resistance exercise pilot interventionCrystal S Langlais, Yea-Hung Chen, Erin L Van Blarigan, et al.
European Urology|October 29, 2015
Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 StudiesJoaquim Bellmunt, Thian Kheoh, Margaret K Yu, et al.
JCO Precision Oncology|January 31, 2025
Digital Pathology-Based Multimodal Artificial Intelligence Scores and Outcomes in a Randomized Phase III Trial in Men With Nonmetastatic Castration-Resistant Prostate CancerFelix Y Feng, Matthew R Smith, Fred Saad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 23, 2022
CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null DiseaseNing Zhao, Shalini Chopra, Kai Trepka, et al.
Frontiers in Oncology|March 24, 2022
APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial CancerDivya Natesan, Li Zhang, Henry J Martell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2020
Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate CancerJames A Eastham, Glenn Heller, Susan Halabi, et al.
Cancer Discovery|April 29, 2017
Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of <i>BRCA2</i> Reversion Mutations Associated with Resistance to PARP InhibitorsDavid Quigley, Joshi J Alumkal, Alexander W Wyatt, et al.
Nature|July 21, 2022
Deep whole-genome ctDNA chronology of treatment-resistant prostate cancerCameron Herberts, Matti Annala, Joonatan Sipola, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2012
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trialDavid C Smith, Matthew R Smith, Christopher Sweeney, et al.
Pageof 37

Showing results (301-310 of 361) with videos related to

Sort By:
Pageof 37
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2023
External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate CancerSusan Halabi, Qian Yang, Akash Roy, et al.
Urologic Oncology|December 17, 2022
Quality of life for men with metastatic castrate-resistant prostate cancer participating in an aerobic and resistance exercise pilot interventionCrystal S Langlais, Yea-Hung Chen, Erin L Van Blarigan, et al.
European Urology|October 29, 2015
Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 StudiesJoaquim Bellmunt, Thian Kheoh, Margaret K Yu, et al.
JCO Precision Oncology|January 31, 2025
Digital Pathology-Based Multimodal Artificial Intelligence Scores and Outcomes in a Randomized Phase III Trial in Men With Nonmetastatic Castration-Resistant Prostate CancerFelix Y Feng, Matthew R Smith, Fred Saad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 23, 2022
CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null DiseaseNing Zhao, Shalini Chopra, Kai Trepka, et al.
Frontiers in Oncology|March 24, 2022
APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial CancerDivya Natesan, Li Zhang, Henry J Martell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2020
Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate CancerJames A Eastham, Glenn Heller, Susan Halabi, et al.
Cancer Discovery|April 29, 2017
Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of <i>BRCA2</i> Reversion Mutations Associated with Resistance to PARP InhibitorsDavid Quigley, Joshi J Alumkal, Alexander W Wyatt, et al.
Nature|July 21, 2022
Deep whole-genome ctDNA chronology of treatment-resistant prostate cancerCameron Herberts, Matti Annala, Joonatan Sipola, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2012
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trialDavid C Smith, Matthew R Smith, Christopher Sweeney, et al.
Pageof 37